Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook

Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.01, $0.39 better than the analyst estimate of $3.62. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.22 billion.

GUIDANCE:

Vertex Pharma sees FY2022 revenue of $8.8-8.9 billion, versus the prior of $8.6-$8.8 billion and the consensus of $8.77 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Vertex signs LoI with the Pan-Canadian Pharmaceutical Alliance for alyftrek for the treatment of cystic fibrosis
• Tepper’s Appaloosa soars 32% in H1 on prescient memory-chip bets - report
• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis